Haemonetics (HAE) Tops Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $120.28 --0%
EPS Growth %: +1.6%
Financial Fact:
Research, development and engineering: 8.34M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +1.6%
Financial Fact:
Research, development and engineering: 8.34M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q1 EPS of $1.10, $0.09 better than the analyst estimate of $1.01. Revenue for the quarter came in at $321.39 million versus the consensus estimate of $302.62 million.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s posts better-than-expected third-quarter comparable sales
- Harmony Biosciences posts Q3 revenue of $269M, reaffirms 2026 outlook
- L.B. Foster (FSTR) Reports In-Line Q3 EPS ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
